Migraine

>

Latest News

AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention / image credit head pain ©jiris/stock.adobe.com
AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention

April 12th 2024

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

Consider CGRP Inhibitors as a First-Line Option for Preventive Treatment of Migraine: New American Headache Society Consensus Statement / image credit - headache: ©peterschreiber.media/stock.adobe.com
Consider CGRP Inhibitors as a First-Line Option for Preventive Treatment of Migraine: New American Headache Society Consensus Statement

April 12th 2024

Atogepant vs Rimegepant for Migraine Prevention: Daily Dose / image credit: ©New Africa/AdobeStock
Atogepant vs Rimegepant for Migraine Prevention: Daily Dose

April 11th 2024

Atogepant Found More Effective for Migraine Prevention vs Rimegepant in New Analysis / image credit migraine headache: ©nataletado/stock.adobe.com
Atogepant Found More Effective for Migraine Prevention vs Rimegepant in New Analysis

April 3rd 2024

©Kateryna_Kon/stock.adobe.com
Erenumab Rx Early in Episodic Migraine Found Superior to Oral Prophylactic Agents for Efficacy, Tolerability, Adherence

April 1st 2024

More News

© 2024 MJH Life Sciences

All rights reserved.